Johnson & Johnson News Today: Acquisition of Halda Therapeutics Paves Way for Cancer Innovation

Johnson & Johnson’s strategic acquisition of Halda Therapeutics, valued at $3.05 billion, marks a pivotal step in advancing cancer treatment innovation. By assimilating Halda’s experimental prostate cancer drug, HLD-0915, J&J has bolstered its oncology segment considerably. This move aligns with J&J’s long-term vision of leading in the development of groundbreaking therapies, reflecting its strong commitment to transforming cancer care.